Home » Correction
Correction
A story in the Oct. 20 edition of Drug Daily Bulletin about Genentech’s third-quarter earnings states that the company is studying Avastin as a potential treatment for rheumatoid arthritis. The company is actually studying Rituxan for this purpose.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May